Virax Biolabs Files Form 6-K with SEC

Ticker: VRAX · Form: 6-K · Filed: Dec 10, 2024 · CIK: 1885827

Virax Biolabs Group Ltd 6-K Filing Summary
FieldDetail
CompanyVirax Biolabs Group Ltd (VRAX)
Form Type6-K
Filed DateDec 10, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-k, regulatory-update

TL;DR

Virax Biolabs filed a 6-K on Dec 10, 2024. Standard update.

AI Summary

On December 10, 2024, Virax Biolabs Group Limited filed a Form 6-K. The filing indicates that the company is a foreign private issuer and is providing information as required by the SEC. The company's principal executive offices are located in Lanarkshire, United Kingdom.

Why It Matters

This filing is a routine update for investors, confirming the company's status and providing basic corporate information as required by regulatory bodies.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not contain new financial information or significant operational updates that would inherently increase risk.

Key Players & Entities

  • Virax Biolabs Group Limited (company) — Registrant
  • December 10, 2024 (date) — Filing date
  • 001-41440 (other) — Commission File Number

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange.

When was this Form 6-K filed?

This Form 6-K was filed on December 10, 2024.

What is the Commission File Number for Virax Biolabs Group Limited?

The Commission File Number for Virax Biolabs Group Limited is 001-41440.

Where are Virax Biolabs Group Limited's principal executive offices located?

The company's principal executive offices are located at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire, ML1 5UH, United Kingdom.

Does Virax Biolabs Group Limited file annual reports under Form 20-F or Form 40-F?

Virax Biolabs Group Limited indicates it files annual reports under Form 20-F.

Filing Stats: 255 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-12-10 07:36:25

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VIRAX BIOLABS GROUP LIMITED Date: December 10, 2024 By: /s/ James Foster James Foster, Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.